NewTimeSpace News: CHINA RES GAS(01193.HK) announced that its wholly-owned subsidiary, China Resources Gas Investment (China), completed the issuance of the Third Tranche MTNs on August 7, with an aggregate principal of RMB 2.5 billion, comprising RMB 1.5 billion three-year notes at a coupon rate of 1.57% per annum and RMB 1.0 billion five-year notes at a coupon rate of 1.70% per annum, with the proceeds to be used to replace bank loans.
NewTimeSpace News: Tailam Tech Construction Holdings announced on 7 August that it expects to record a consolidated loss of about RMB2.3 million for the six months ended 30 June 2026, compared with an unaudited consolidated profit of approximately RMB6.4 million in the corresponding period last year, marking a swing from profit to loss.
NewTimeSpace News: China Resources Gas announced on 7 August that its wholly-owned subsidiary China Resources Gas Investment (China) completed the issuance of the third series of medium-term notes on 7 August 2026, with an aggregate principal amount of RMB2.5 billion.
NewTimeSpace News: EASYKNIT INT'L (01218.HK) issued a voluntary announcement clarifying media reports and market rumors on the potential sale of the "Sum Lei" property on Chatham Road North, Kowloon, confirming that the Group is in discussions with independent third parties over the potential disposal without any final or binding agreement reached, and reminded shareholders and potential investors to act with caution when trading the Company's securities.
NewTimeSpace News: August 07, 2026, CABBEEN(02030.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 452.86 million, increased by 7.24% YoY
NewTimeSpace News: SHIFANG HLDG (01831.HK) announced that a paper-based share transfer application involving 75,759,903 shares (more than 5% of total share capital) was rejected by the Board over suspected major illegal insider dealing, and the transaction failed, with the ultimate beneficiaries being Mr. Chen Jiaxuan and Mr. Chen Jiarui; the Company has engaged criminal lawyers and intends to pursue legal action.
NewTimeSpace News: HANG LUNG GROUP (00010.HK) and HANG LUNG PPT (00101.HK) jointly announced the appointment of Mr. Leo Tsoi as executive director and CEO designate, effective September 7, who will succeed Mr. Weber Wai Pak Lo as CEO from October 1, with an annual salary of HKD 20,520,000; Mr. Lo will serve as advisor to the chairman for one year after stepping down on September 30.
NewTimeSpace News: EDDING GENOR (06998.HK): The first subject has been dosed in the Phase Ib/II clinical trial of the PD-1/CTLA-4/VEGF trispecific antibody GB268 for locally advanced unresectable or metastatic breast cancer on 5 August 2026, with the study covering monotherapy and combination chemotherapy/ADC regimens; Phase I monotherapy data are planned to be presented at ESMO in Q4 2026.
NewTimeSpace News: TSAKER NE (01986.HK): Shandong Tsaker New Materials, an indirect non-wholly-owned subsidiary, entered into a joint venture agreement with Zijin Lithium to establish a joint venture with a registered capital of RMB 93.2 million for the iron phosphate business, with the Group side holding 55%; the transaction constitutes a discloseable transaction exempt from the circular and shareholders' approval requirements.
NewTimeSpace News: JIANGXI BANK (01916.HK): The Board proposes to privately place up to 715,000,000 domestic shares and 215,000,000 H shares under a specific mandate, with the net proceeds used in full to replenish core Tier 1 capital; the domestic share issuance targets up to 35 domestic institutional investors, the H share issue price will not be lower than the benchmark price, and an EGM and class meetings will be convened to seek approval.
NewTimeSpace News: MINTH GROUP (00425.HK): The Group held a groundbreaking ceremony for its new production plant in Gadsden, Alabama, US, with planned phased investment of approximately USD 430 million; first-phase capacity is expected to commence production in 2027, and upon completion the plant will create more than 1,300 jobs and become the Group's largest site globally.
NewTimeSpace News: CARSGEN-B (02171.HK): The universal CAR-T product CT1190B targeting CD19/CD20 has received IND approval from the NMPA for the treatment of patients with R/R LBCL who have failed at least two lines of standard therapy; the product was developed on the THANK-u Plus platform, with IIT results presented as a poster at the 2026 EHA annual meeting.
NewTimeSpace News: IMMUNEONCO-B (01541.HK): The Company's non-wholly-owned subsidiary Yiming Kaier received a capital increase of RMB 50 million in total consideration from investors including Shengke Qihang, Xinjie Chuangyuan and Mr. Wang Xueyan, with the investors subscribing for approximately 15.83% of the enlarged equity; upon completion the Company will hold approximately 68.34%, the target company will remain a non-wholly-owned subsidiary, and the transaction is fully exempt from Chapter 14 of the Listing Rules.
NewTimeSpace News: CHK OIL (00632.HK): Mr. Zheng Zhensheng has resigned as CFO, company secretary, authorised representative and process agent with effect from 7 August 2026; following the resignation the Company is temporarily not in compliance with Rules 3.05, 3.28 and 19.05(2) of the Listing Rules relating to authorised representatives, company secretary and process agent, and is seeking candidates to fill the vacancies as soon as practicable.
NewTimeSpace News: TONTINE WINES (00389.HK): The Company received notice of court proceedings commenced by Shuntuo Development Limited and Mr. Wang He in the High Court of Hong Kong (Miscellaneous Proceedings No. 1316 of 2026) over the placing agreement, seeking declarations that the agreement is void and injunctions; the Company intends to actively defend, and the Board considers the proceedings have no immediate material adverse impact on the Group's existing business operations or financial position.
NewTimeSpace News: TRANSCENTA-B (06628.HK): The Company's wholly-owned subsidiary proposes to dispose of its CDMO assets to a wholly-owned subsidiary of WuXi Biologics for RMB 190 million, with an estimated loss of approximately RMB 280 million to be recognised; the transaction constitutes a major transaction subject to shareholders' approval, with the circular expected to be despatched on or before 25 August 2026.
